SMHGF.US Simcere Pharmaceutical Group Limited

Healthcare Drug Manufacturers - Specialty & Generic USA Stocks
1.35 USD
Close of Nov 17, 2026
0.6799 1.93
Market cap
USD 3.45B
P/E
15.0x
P/B
2.44x
ROE
14.3%
Dividend yield
1.95%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is SMHGF.US undervalued?

Graham number
Price1.35
Graham value1.06
Premium27.6%

SMHGF.US trades 27.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Simcere Pharmaceutical Group Limited fundamental analysis

No fundamental analysis for Simcere Pharmaceutical Group Limited yet.

Simcere Pharmaceutical Group Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Simcere Pharmaceutical Group Limited

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Ra; Zemprocitinib a highly selective JAK1 inhibitor; and Xianlinda, an inhibitor f…

Full company profile